




|                          |  | EMLc               | ATC codes: L01BC01 |
|--------------------------|--|--------------------|--------------------|
| Indication               | Myeloid leukaemia  | ICD11 code: 2C03.1 |                    |
| INN                      | Cytarabine   |                    |                    |
| Medicine type            | Chemical agent   |                    |                    |
| List type                | Complementary (EML) (EMLc)   |                    |                    |
| Formulations             | Parenteral > General injections > unspecified: 100 mg in vial powder for injection ; 100 mg per mL in vial   |                    |                    |
| EML status history       | First added in 1979 (TRS 641)<br>Changed in 2015 (TRS 994)<br>Changed in 2019 (TRS 1021)<br>Changed in 2023 (TRS 1049)   |                    |                    |
| Sex                      | All  |                    |                    |
| Age                      | Also recommended for children  |                    |                    |
| Therapeutic alternatives | The recommendation is for this specific medicine   |                    |                    |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |                    |                    |
| Tags                     | <a href="#">Cancer</a>   |                    |                    |
| Wikipedia                | <a href="#">Cytarabine</a>    |                    |                    |
| DrugBank                 | <a href="#">Cytarabine</a>    |                    |                    |

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.

